Development of cabozantinib for the treatment of prostate cancer

References

• Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363(5):411–422.
   PubMed Web of Science ®Google Scholar
• De Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364(21):1995–2005.
   PubMed Web of Science ®Google Scholar
• De Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376(9747):1147–1154.
   PubMed Web of Science ®Google Scholar
• Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367(13):1187–1197.
   PubMed Web of Science ®Google Scholar
• Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369(3):213–223.
   PubMed Web of Science ®Google Scholar
• Smith DC, Smith MR, Sweeney C, et al. Cabozantinib in patients with advanced prostate cancer: results of a Phase II randomized discontinuation trial. J Clin Oncol. 2013;31(4):412–419.
   PubMed Web of Science ®Google Scholar
• Yakes FM, Chen J, Tan J, et al. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther. 2011;10(12):2298–2308.
   PubMed Web of Science ®Google Scholar
• Elisei R, Schlumberger MJ, Müller SP, et al. Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol. 2013;31(29):3639–3646.
   PubMed Web of Science ®Google Scholar
• Humphrey PA, Zu X, Zarnegar R, et al. Hepatocyte growth factor and HS receptor (c-Met) in prostatic carcinoma. Am J Pathol. 1995;147(2):386–396.
   PubMed Web of Science ®Google Scholar
• Knudsen BS, Gmyrek GA, Inra J, et al. High expression of the Met receptor in prostate cancer metastasis to bone. Urology. 2002;60(6):1113–1117.
   PubMed Web of Science ®Google Scholar
• Pàez-Ribes M, Allen E, Hudock J, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell. 2009;15(3):220–231.
   PubMed Web of Science ®Google Scholar
• Schmidt L, Duh FM, Chen F, et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet. 1997;16(1):68–73.
   PubMed Web of Science ®Google Scholar
• Sennino B, Ishiguro-Oonuma T, Wei Y, et al. Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumors. Cancer Discov. 2012;9(3):270–287.
   Google Scholar
• You WK, Sennino B, Williamson CW, et al. VEGF and c-Met blockade amplify angiogenesis inhibition in pancreatic islet cancer. Cancer Res. 2011;71(14):4758–4768.
   PubMed Web of Science ®Google Scholar
• Aftab DT, McDonald DM. MET and VEGF: synergistic targets in castration-resistant prostate cancer. Clin Transl Oncol. 2011;13(10):703–709.
   PubMed Web of Science ®Google Scholar
• Sennino B, Naylor RM, Tabruyn SB, You WK, Aftab DT, McDonald DM. Reduction of tumor invasiveness and metastasis and prolongation of survival of RIP-Tag2 mice after inhibition of VEGFR plus c-Met by XL184. Mol Cancer Ther. 2009;8(Suppl 12):A13.
   Web of Science ®Google Scholar
• Sennino B, Ishiguro-Oonuma T, Schriver BJ, et al. Inhibition of c-Met reduces lymphatic metastasis in RIP-Tag2 transgenic mice. Cancer Res. 2013;73(12):3692–3703.
   PubMed Web of Science ®Google Scholar
• Street J, Lenehan B. Vascular endothelial growth factor regulates osteoblast survival: evidence for an autocrine feedback mechanism. J Orthop Surg Res. 2009;4:19–23.
   PubMedGoogle Scholar
• Grano M, Galimi F, Zambonin G, et al. Hepatocyte growth factor is a coupling factor for osteoclasts and osteoblasts in vitro. Proc Natl Acad Sci U S A. 1996;93(15):7644–7648.
   PubMed Web of Science ®Google Scholar
• Schimmoller F, Zayzafoon M, Chung LWK, et al. Cabozantinib (XL184), a dual MET-VEGFR2 inhibitor, blocks osteoblastic and osteolytic progression of human prostate cancer xenografts in mouse bone. Mol Cancer Ther. 2011;10(11 Suppl 1):233.
   PubMedGoogle Scholar
• Ono K, Kamiya S, Akatsu T, et al. Involvement of hepatocyte growth factor in the development of bone metastasis of a mouse mammary cancer cell line, BALB/c-MC. Bone. 2006;39(1):27–34.
   PubMed Web of Science ®Google Scholar
• Dai J, Zhang H, Karatsinides A, et al. Cabozantinib inhibits prostate cancer growth and inhibits tumor induced bone lesions. Clin Cancer Res. 2014;20(3):617–630.
   PubMed Web of Science ®Google Scholar
• Pennacchietti S, Michieli P, Galluzzo M, et al. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell. 2003;3(4):347–361.
   PubMed Web of Science ®Google Scholar
• Fernando NT, Koch M, Rothrock C, et al. Tumor escape from endogenous, extracellular matrix-associated angiogenesis inhibitors by up-regulation of multiple proangiogenic factors. Clin Cancer Res. 2008;14(5):1529–1539.
   PubMed Web of Science ®Google Scholar
• Kelly WK, Halabi S, Carducci M, et al. Randomized, double-blind, placebo-controlled Phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. J Clin Oncol. 2012;30(13):1534–1540.
   PubMed Web of Science ®Google Scholar
• Tannock I, Fizazi K, Sergei I, et al. Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a Phase 3, double-blind randomised trial. Lancet Oncol. 2013;14(8):760–768.
   PubMed Web of Science ®Google Scholar
• Eder JP, Vande Woude GF, Boerner SA, LoRusso PM. Novel therapeutic inhibitors of the c-Met signaling pathway in cancer. Clin Cancer Res. 2009;15(7):2207–2214.
   PubMed Web of Science ®Google Scholar
• Vankayala H, Lorusso P, Vaishampayan UN. C-MET as a novel target for the treatment of renal cell carcinoma. In: Figlin RA, Rathmell WK, Rini BI, editors. Renal Cell Carcinoma. New York, NY, USA: Springer; 2012.
   Google Scholar
• Kurzrock R, Sherman SI, Ball DW, et al. Activity of XL184 (cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol. 2011;29(19):2660–2666.
   PubMed Web of Science ®Google Scholar
• Lee RJ, Saylor PJ, Michaelson MD, et al. A dose-ranging study of cabozantinib in men with castration-resistant prostate cancer and bone metastases. Clin Cancer Res. 2013;19(11):3088–3094.
   PubMed Web of Science ®Google Scholar
• Exelixis. Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100 (COMET-1). Available from: http://clinicaltrials.gov/show/NCT01605227. NLM identifier: NCT01605227. Accessed March 25, 2014.
   Google Scholar
• Barbara Ann Karmanos Cancer Institute. Cabozantinib-S-Malate in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer. Available from: http://clinicaltrials.gov/show/NCT01812668. NLM identifier: NCT01812668. Accessed March 25, 2014.
   Google Scholar